The Role of Simvastatin in the Epithelial-Mesenchymal Transition Process of Breast Cancer

Launched by INDONESIA UNIVERSITY · Sep 19, 2022

Keywords

ClinConnect Summary

This clinical trial is studying the effects of a medication called simvastatin in combination with standard chemotherapy for women with a specific type of breast cancer known as triple-negative breast cancer (TNBC). TNBC is known to be aggressive and can be challenging to treat. The researchers want to see if simvastatin can help improve the treatment response by affecting a process called epithelial-mesenchymal transition (EMT), which is linked to how cancer spreads and can make it harder for treatments to work.

To participate in this trial, women must be over 18 years old and have been diagnosed with advanced triple-negative breast cancer confirmed by a biopsy. They should also be planning to receive eight cycles of a specific chemotherapy regimen. Participants will be randomly assigned to receive either simvastatin along with their chemotherapy or a placebo (a harmless pill with no active ingredients). Throughout the trial, researchers will monitor any side effects and check how well the treatment is working by looking at tissue samples from biopsies taken before and after the treatment. If you or someone you know is considering joining this trial, it could be a chance to contribute to important research while receiving treatment.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • 1. Female patients with advanced breast cancer (locally advanced and distantly advanced) with triple-negative molecular type confirmed by biopsy and immunohistochemical examination.
• • 2. The patient planned to receive 8 cycles of AC-T chemotherapy.
• • 3. Patient age \> 18 years.
• • 4. Willing to participate in research by signing informed consent.
• Exclusion Criteria:
• • 1. The patient is pregnant or breastfeeding.
• • 2. Patients who have received chemotherapy or are on simvastatin therapy.
• • 3. Allergy to statins.